Critical Analysis: BioRestorative Therapies (BRTX) vs. Its Rivals

BioRestorative Therapies (OTCMKTS:BRTXGet Free Report) is one of 425 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare BioRestorative Therapies to similar businesses based on the strength of its dividends, analyst recommendations, valuation, profitability, risk, earnings and institutional ownership.

Valuation and Earnings

This table compares BioRestorative Therapies and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BioRestorative Therapies $145,800.00 -$18.50 million -0.37
BioRestorative Therapies Competitors $147.61 million -$9.44 million 102.59

BioRestorative Therapies’ rivals have higher revenue and earnings than BioRestorative Therapies. BioRestorative Therapies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current recommendations and price targets for BioRestorative Therapies and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioRestorative Therapies 0 0 1 0 3.00
BioRestorative Therapies Competitors 628 2049 4795 52 2.57

BioRestorative Therapies currently has a consensus price target of $15.00, indicating a potential upside of 1,045.04%. As a group, “Biotechnology” companies have a potential upside of 83.06%. Given BioRestorative Therapies’ stronger consensus rating and higher probable upside, research analysts plainly believe BioRestorative Therapies is more favorable than its rivals.

Institutional and Insider Ownership

69.4% of BioRestorative Therapies shares are held by institutional investors. Comparatively, 29.1% of shares of all “Biotechnology” companies are held by institutional investors. 21.6% of BioRestorative Therapies shares are held by insiders. Comparatively, 22.4% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

BioRestorative Therapies has a beta of 62.12, suggesting that its stock price is 6,112% more volatile than the S&P 500. Comparatively, BioRestorative Therapies’ rivals have a beta of 1.24, suggesting that their average stock price is 24% more volatile than the S&P 500.

Profitability

This table compares BioRestorative Therapies and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioRestorative Therapies -13,728.83% -120.47% -114.48%
BioRestorative Therapies Competitors -9,009.53% -129.35% -25.27%

Summary

BioRestorative Therapies rivals beat BioRestorative Therapies on 7 of the 13 factors compared.

About BioRestorative Therapies

(Get Free Report)

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Receive News & Ratings for BioRestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioRestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.